Invenra has launched its Rapid Antibody Discovery Service, designed to simplify and de-risk the preclinical development of ...

Hanx Biopharmaceuticals, CO. Ltd, an innovative biotechnology company developing next-generation immunotherapies to address the challenges of unmet medical need diseases, today announced the first ...

Background Panitumumab is a fully human antibody against the epidermal growth factor receptor that is indicated for the treatment of metastatic colorectal cancer (mCRC) after disease progression ...

The total market size of eosinophilic esophagitis in 2023 was approximately USD 1.80 trillion in the 7MM, which is expected to grow during the forecast period (2020-2034). Among EU4 and the UK, ...

The resulting cells produce fully human antibodies, as opposed to the chimeric or humanised antibodies produced by the alternative methods. 4 Multiple disciplines need to come together to meet the ...

“Our unique RenMice ® platform enables the discovery of fully human antibodies with high affinity, low immunogenicity, and favorable developability. With Adcendo’s extensive expertise in ...

Ersodetug is under clinical development by Rezolute and currently in Phase II for Hyperinsulinemia. According to GlobalData, Phase II drugs for Hyperinsulinemia does not have sufficient historical ...

The company then identified over 500 unique fully human antibody sequences – which it says is the largest panel of antiSARS-CoV-2 antibodies ever reported – before screening those antibodies ...

Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Polymyositis. According to GlobalData, Phase III drugs for Polymyositis does not have sufficient historical data ...

INR:0603. rummy the card game Jinghua Pharmaceuticals terminates the development of two fully human monoclonal antibody products "Pharmaceutical Speed ​​R ...